US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

First Trust NYSE Arca Biotechnology Index Fund

272.33

+4.491.68%

Volume:26.38K

Turnover:7.13M

Market Cap:2.95B

PE:31.87

High:273.09

Open:267.37

Low:267.37

Close:267.84

52wk High:274.81

52wk Low:173.87

Shares:10.85M

Float Shares:10.85M

Volume Ratio:0.94

T/O Rate:0.24%

Dividend:- -

Dividend Rate:- -

EPS(TTM):8.55

EPS(LYR):37.75

ROE:19.96%

ROA:-0.16%

PB:2.22

PE(LYR):7.21

Loading ...

Overview Company News Filings

Does NeoGenomics (NEO) New PTEN CDx Move Reveal a Deeper Precision Oncology Strategy Shift?

Simply Wall St.

Voyager Therapeutics advances tau-silencing gene therapy program

Analysts Conflicted on These Healthcare Names: Alkermes (ALKS), TransMedics Group (TMDX) and Praxis Precision Medicines (PRAX)

Alkermes Plc : TD Cowen Raises Target Price to $57 from $50

THOMSON REUTERS

Alkermes Price Target Announced at $60.00/share by JP Morgan

Alkermes Says Alixorexton Sustains Wakefulness Gains in Nine-month Narcolepsy Extension Study Interim Analysis

Alkermes - Alixorexton Generally Well Tolerated at All Doses Tested

THOMSON REUTERS

Alkermes - Alixorexton Shows Sustained Improvement on Mwt and ESS at Week 24, Nine Months After First Dose

THOMSON REUTERS

Alkermes’ Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults with Narcolepsy Type 1 and Type 2 in Long-term Extension Study Interim Analysis

THOMSON REUTERS

Bank of America Securities Remains a Sell on Alkermes (ALKS)

Brookfield in Exclusive Talks to Acquire Stake in Hudson Square Portfolio, Betting on Manhattan's Tech Hub

Alkermes Plc : JP Morgan Resumes Coverage with Neutral Rating; Target Price $60

THOMSON REUTERS

Bruker Files Form 3 for BMID Group President Wolfgang Pusch Stake

Press Release: Veracyte to Release Second Quarter 2026 Financial Results on July 30, 2026

Veracyte to Report Q2 Results, Host Conference Call

Is Corcept Therapeutics (CORT) Fully Valued On Its Russell Index Removal?

Simply Wall St.

Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS) and Immunome (IMNM)

NeoGenomics Launches First FDA-Approved Prostate Cancer Companion Diagnostic

Veracyte Inc : Morgan Stanley Raises Target Price to $47.00 from $37.00

THOMSON REUTERS

NeoGenomics launches FDA-approved PTEN IHC prostate Cancer ompanion diagnostic

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/FBT/news?page=10"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"FBT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FBT\",,,,,undefined,":{"symbol":"FBT","market":"US","secType":"STK","nameCN":"First Trust NYSE Arca Biotechnology Index Fund","latestPrice":272.33,"timestamp":1788373162495,"preClose":267.84,"halted":0,"volume":26376,"delay":0,"changeRate":0.016763739545997646,"floatShares":10850002,"shares":10850002,"eps":8.545272,"marketStatus":"Trading","change":4.49,"latestTime":"09-02 14:20:16 EDT","open":267.37,"high":273.0901,"low":267.37,"amount":7125220.552800001,"amplitude":0.021356,"askPrice":272.69,"askSize":16,"bidPrice":272.5,"bidSize":7,"shortable":3,"etf":1,"ttmEps":8.545272,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1788379200000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":267.84,"sharesOutstanding":11450002,"nav":267.27,"aum":2913243534.54,"bidAskSpread":0.001063,"preHourTrading":{"tag":"盘前","latestPrice":267.96,"preClose":267.84,"latestTime":"07:52 EDT","volume":5,"amount":1334.34,"timestamp":1788349977151,"change":0.12,"changeRate":0.000448,"amplitude":0.000448},"postHourTrading":{"tag":"盘后","latestPrice":267.84,"preClose":267.84,"latestTime":"19:44 EDT","volume":19,"amount":5092.48,"timestamp":1788306289404,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.937821,"impliedVol":0.202,"impliedVolPercentile":0.4167},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FBT\",,,,,undefined,":{"symbol":"FBT","floatShares":10850002,"roa":"-0.16%","roe":"19.96%","lyrEps":37.754725,"volumeRatio":0.937821,"shares":10850002,"dividePrice":0,"high":273.0901,"amplitude":0.021356,"preClose":267.84,"low":267.37,"week52Low":173.8701,"pbRate":"2.22","psRate":"1087.96","week52High":274.81,"institutionHeld":0,"latestPrice":272.33,"committee":-0.391304,"eps":8.545272,"divideRate":0,"volume":26376,"delay":0,"ttmEps":8.545272,"open":267.37,"prevYearClose":206.52,"prevWeekClose":266.95,"prevMonthClose":267.15,"prevQuarterClose":247.89,"fiveDayClose":272.07,"twentyDayClose":249,"sixtyDayClose":221.15},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/FBT\",params:#limit:5,,,undefined,":[{"date":"2024-12-13","symbol":"FBT","amount":1.1726,"announcedDate":"2024-12-12","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-13","defaultRemindTime":1734100200000,"name":"First Trust NYSE Arca Biotechnology Index Fund","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-31","payableDate":"2024-12-13","currency":"USD","dateTimestamp":1734066000000,"payDate":"2024-12-31"},{"market":"US","date":"2022-01-10","symbol":"FBT","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1641790800000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2021-12-30","symbol":"FBT","amount":2.2136,"defaultRemindTime":1640874600000,"name":"First Trust NYSE Arca Biotechnology Index Fund","recordDate":"2022-01-10","payableDate":"2021-12-31","currency":"USD","type":"dividend","dateTimestamp":1640840400000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"FBT\",market:\"US\",,,undefined,":[{"executeDate":"2021-12-30","recordDate":"2021-12-31","paymentDate":"2022-01-10","value":2.2136,"currency":"USD"},{"executeDate":"2024-12-13","recordDate":"2024-12-13","paymentDate":"2024-12-31","value":1.1726,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"FBT\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"FBT\",pageSize:20,pageCount:10,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2651430120","title":"Does NeoGenomics (NEO) New PTEN CDx Move Reveal a Deeper Precision Oncology Strategy Shift?","url":"https://stock-news.laohu8.com/highlight/detail?id=2651430120","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651430120?lang=en_us&edition=fundamental","pubTime":"2026-07-14 14:29","pubTimestamp":1784010575,"startTime":"0","endTime":"0","summary":"In July 2026, NeoGenomics, Inc. launched PTEN IHC CDx, the first FDA-approved immunohistochemistry companion diagnostic for prostate adenocarcinoma, enabling identification of PTEN-deficient tumors in patients who may be eligible for AstraZeneca’s TRUQAP (capivasertib), with testing available across its national oncology laboratory network.\nThis test not only extends NeoGenomics’ presence into urologic oncology but also deepens its role in personalized prostate cancer care through rapid,...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-neo/neogenomics/news/does-neogenomics-neo-new-pten-cdx-move-reveal-a-deeper-preci","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-neo/neogenomics/news/does-neogenomics-neo-new-pten-cdx-move-reveal-a-deeper-preci","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NEO","BK4196","LU0012050646.USD","BK4092","FBT","BK4121","PTEN","LU0106261612.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651145087","title":"Voyager Therapeutics advances tau-silencing gene therapy program","url":"https://stock-news.laohu8.com/highlight/detail?id=2651145087","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651145087?lang=en_us&edition=fundamental","pubTime":"2026-07-14 01:27","pubTimestamp":1783963636,"startTime":"0","endTime":"0","summary":"Voyager Therapeutics ( ($VYGR) ) has provided an update. On July 13, 2026, Voyager Therapeutics presented three- and six-month good laboratory prac...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/voyager-therapeutics-advances-tau-silencing-gene-therapy-program?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/voyager-therapeutics-advances-tau-silencing-gene-therapy-program?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VYGR","IBBQ","BK4139","GNOM","CNCR","IBB","SYNB","BK4585","FBT","LFSC","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651143954","title":"Analysts Conflicted on These Healthcare Names: Alkermes (ALKS), TransMedics Group (TMDX) and Praxis Precision Medicines (PRAX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2651143954","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651143954?lang=en_us&edition=fundamental","pubTime":"2026-07-14 00:10","pubTimestamp":1783959019,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Alkermes (ALKS), TransMedics Group (TMDX) and Praxis Precision Me...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-alkermes-alks-transmedics-group-tmdx-and-praxis-precision-medicines-prax-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-alkermes-alks-transmedics-group-tmdx-and-praxis-precision-medicines-prax-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128526141.USD","LU2324357040.USD","LU0889565916.HKD","LU0029874061.USD","BK4137","BK4588","BK4139","BK4082","MEDX","LABU","ALKS","FBT","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","BK4585","PRAX","LU0320765992.SGD","IE00B4R5TH58.HKD","IE0009355771.USD","IE0002141913.USD","HCSG","BK4581","PSCH","IE00BJJMRZ35.SGD","XBI","XLV","PSIL","TMDX","IE00BJT1NW94.SGD","IBRN","LU0109394709.USD","LU2065731478.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651128211","title":"Alkermes Plc : TD Cowen Raises Target Price to $57 from $50","url":"https://stock-news.laohu8.com/highlight/detail?id=2651128211","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651128211?lang=en_us&edition=fundamental","pubTime":"2026-07-13 21:29","pubTimestamp":1783949398,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260713:nFWN43F0V4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FBT","PSIL","ALKS","MEDX","IBRN","PSCH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651115701","title":"Alkermes Price Target Announced at $60.00/share by JP Morgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2651115701","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651115701?lang=en_us&edition=fundamental","pubTime":"2026-07-13 19:10","pubTimestamp":1783941000,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ALKS/analyst-ratings(END) Dow Jones NewswiresJuly 13, 2026 07:10 ET","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSIL","BK4139","PSCH","IBRN","ALKS","MEDX","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651115250","title":"Alkermes Says Alixorexton Sustains Wakefulness Gains in Nine-month Narcolepsy Extension Study Interim Analysis","url":"https://stock-news.laohu8.com/highlight/detail?id=2651115250","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651115250?lang=en_us&edition=fundamental","pubTime":"2026-07-13 19:01","pubTimestamp":1783940468,"startTime":"0","endTime":"0","summary":"Alkermes says alixorexton sustains wakefulness gains in nine-month narcolepsy extension study interim analysisAlkermes reported interim long-term extension results showing alixorexton sustained clinic","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260713:nNDL7r2w61:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRN","BK4139","MEDX","PSIL","PSCH","ALKS","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651904115","title":"Alkermes - Alixorexton Generally Well Tolerated at All Doses Tested","url":"https://stock-news.laohu8.com/highlight/detail?id=2651904115","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651904115?lang=en_us&edition=fundamental","pubTime":"2026-07-13 19:00","pubTimestamp":1783940428,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260713:nFWN43D02G:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALKS","IBRN","MEDX","PSCH","PSIL","BK4139","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651115976","title":"Alkermes - Alixorexton Shows Sustained Improvement on Mwt and ESS at Week 24, Nine Months After First Dose","url":"https://stock-news.laohu8.com/highlight/detail?id=2651115976","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651115976?lang=en_us&edition=fundamental","pubTime":"2026-07-13 19:00","pubTimestamp":1783940428,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260713:nFWN43D02G:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IBRN","FBT","MEDX","PSCH","ALKS","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651115189","title":"Alkermes’ Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults with Narcolepsy Type 1 and Type 2 in Long-term Extension Study Interim Analysis","url":"https://stock-news.laohu8.com/highlight/detail?id=2651115189","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651115189?lang=en_us&edition=fundamental","pubTime":"2026-07-13 19:00","pubTimestamp":1783940428,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260713:nFWN43D02G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IBRN","FBT","BK4139","ALKS","MEDX","PSIL","PSCH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651192046","title":"Bank of America Securities Remains a Sell on Alkermes (ALKS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2651192046","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651192046?lang=en_us&edition=fundamental","pubTime":"2026-07-13 16:45","pubTimestamp":1783932314,"startTime":"0","endTime":"0","summary":"In a report released on July 10, Jason Gerberry from Bank of America Securities maintained a Sell rating on Alkermes, with a price target of $38.00...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/bank-of-america-securities-remains-a-sell-on-alkermes-alks-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/bank-of-america-securities-remains-a-sell-on-alkermes-alks-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2133065610.SGD","LU1506573853.SGD","IYF","LU0130102774.USD","FNCL","LU0130518102.USD","LU0234572021.USD","LU0868494617.USD","LU0070302665.USD","BK4207","LU0648000940.SGD","LU0648001328.SGD","LU1201861249.SGD","LU0211331839.USD","PGF","LU0320765489.SGD","LU0321505439.SGD","LU0980610538.SGD","UYG","PSIL","BAC","XLF","MEDX","IE00BZ1G4Q59.USD","ALKS","LU0203347892.USD","LU0106831901.USD","LU0417517546.SGD","LU2265009873.SGD","LU0306806265.USD","FBT","KBWB","IE00BLSP4452.SGD","LU0256863902.USD","FTXO","LU0208291251.USD","IBRN","LU1363072403.SGD","LU1718418525.SGD","VFH","IE00B19Z3581.USD","BK4581","LU1894683264.USD","IYG","LU0306807586.USD","BK4559","LU2129689514.USD","LU1894683348.USD","LU0640476718.USD","PSCH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113947751","title":"Brookfield in Exclusive Talks to Acquire Stake in Hudson Square Portfolio, Betting on Manhattan's Tech Hub","url":"https://stock-news.laohu8.com/highlight/detail?id=1113947751","media":"Deep News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1113947751?lang=en_us&edition=fundamental","pubTime":"2026-07-13 16:21","pubTimestamp":1783930870,"startTime":"0","endTime":"0","summary":"Real estate giant Brookfield is in exclusive negotiations to acquire a stake in Hudson Square Properties, a deal valuing the portfolio at $3.5 billion and further cementing the status of Manhattan's...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBT","LU1815336091.USD","BK4121","TINY","BRKR","LU0757428866.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651193713","title":"Alkermes Plc : JP Morgan Resumes Coverage with Neutral Rating; Target Price $60","url":"https://stock-news.laohu8.com/highlight/detail?id=2651193713","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651193713?lang=en_us&edition=fundamental","pubTime":"2026-07-13 13:58","pubTimestamp":1783922324,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260713:nFWN43F04A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PSCH","IBRN","ALKS","PSIL","FBT","BK4139","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650813759","title":"Bruker Files Form 3 for BMID Group President Wolfgang Pusch Stake","url":"https://stock-news.laohu8.com/highlight/detail?id=2650813759","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650813759?lang=en_us&edition=fundamental","pubTime":"2026-07-11 04:28","pubTimestamp":1783715316,"startTime":"0","endTime":"0","summary":"Bruker files Form 3 for BMID Group President Wolfgang Pusch stakeBruker Form 3 showed Wolfgang Pusch, president of the BMID Group, held 10,154 shares of common stock as of July 1, 2026.Disclaimer:This","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260710:nNDL1vLFQD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1815336091.USD","TINY","FBT","BRKR","BK4121","LU0757428866.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650972435","title":"Press Release: Veracyte to Release Second Quarter 2026 Financial Results on July 30, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2650972435","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650972435?lang=en_us&edition=fundamental","pubTime":"2026-07-10 05:10","pubTimestamp":1783631400,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--July 09, 2026--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the second ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","VCYT","03160","BK4232","BK4555","R","BK4585","BK4139","BK4604","BK4099","TM","BK4588","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650974538","title":"Veracyte to Report Q2 Results, Host Conference Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2650974538","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650974538?lang=en_us&edition=fundamental","pubTime":"2026-07-10 04:05","pubTimestamp":1783627519,"startTime":"0","endTime":"0","summary":"Veracyte to report Q2 results, host conference callVeracyte schedules release of second-quarter 2026 financial results for July 30, 2026.Management to host a conference call, webcast on July 30, 2026 ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260709:nNDL9vhjk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FBT","VCYT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650976961","title":"Is Corcept Therapeutics (CORT) Fully Valued On Its Russell Index Removal?","url":"https://stock-news.laohu8.com/highlight/detail?id=2650976961","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650976961?lang=en_us&edition=fundamental","pubTime":"2026-07-10 00:32","pubTimestamp":1783614761,"startTime":"0","endTime":"0","summary":"What Corcept’s Index Removal Could Mean for Investors\nCorcept Therapeutics (CORT) was recently removed from the Russell 1000 Growth Defensive Index and the Russell 1000 Defensive Index, a shift that can influence trading activity as index funds rebalance positions.\nFor you as an investor, these index changes are less about Corcept Therapeutics business operations and more about how institutional owners that track these benchmarks may adjust their holdings. Such rebalancing can affect short...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cort/corcept-therapeutics/news/is-corcept-therapeutics-cort-fully-valued-on-its-russell-ind","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cort/corcept-therapeutics/news/is-corcept-therapeutics-cort-fully-valued-on-its-russell-ind","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["PSCH","FBT","BK4532","CORT","LU1559883803.SGD","LU0566484027.USD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650292217","title":"Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS) and Immunome (IMNM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2650292217","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650292217?lang=en_us&edition=fundamental","pubTime":"2026-07-09 21:10","pubTimestamp":1783602606,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Alkermes (ALKS) and Immunome (IMNM) with bullish sen...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-alkermes-alks-and-immunome-imnm-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-alkermes-alks-and-immunome-imnm-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XLV","IMNM","MEDX","XBI","HCSG","PSCH","IBRN","BK4137","LABU","BK4563","BK4581","BK4588","LU0128526141.USD","PSIL","ALKS","BK4139","LU0029874061.USD","FBT","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112561177","title":"NeoGenomics Launches First FDA-Approved Prostate Cancer Companion Diagnostic","url":"https://stock-news.laohu8.com/highlight/detail?id=1112561177","media":"Deep News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1112561177?lang=en_us&edition=fundamental","pubTime":"2026-07-09 20:50","pubTimestamp":1783601450,"startTime":"0","endTime":"0","summary":"NeoGenomics (NASDAQ: NEO) has announced the launch of the PTEN IHC CDx assay, the first immunohistochemistry companion diagnostic for prostate adenocarcinoma patients to receive approval from the...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","BK4196","LU0012050646.USD","LABU","NEO","LU0106261612.USD","FBT","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650592935","title":"Veracyte Inc : Morgan Stanley Raises Target Price to $47.00 from $37.00","url":"https://stock-news.laohu8.com/highlight/detail?id=2650592935","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650592935?lang=en_us&edition=fundamental","pubTime":"2026-07-09 19:32","pubTimestamp":1783596774,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260709:nAZN4T6V3M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FBT","BK4139","VCYT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650926253","title":"NeoGenomics launches FDA-approved PTEN IHC prostate Cancer ompanion diagnostic","url":"https://stock-news.laohu8.com/highlight/detail?id=2650926253","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650926253?lang=en_us&edition=fundamental","pubTime":"2026-07-09 19:10","pubTimestamp":1783595410,"startTime":"0","endTime":"0","summary":"NeoGenomics (NEO) announced the launch of PTEN IHC CDx, the first immunohistochemistry companion diagnostic test approved by the FDA for patients w...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/neogenomics-launches-fda-approved-pten-ihc-prostate-cancer-ompanion-diagnostic-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/neogenomics-launches-fda-approved-pten-ihc-prostate-cancer-ompanion-diagnostic-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FBT","BK4585","LABU","IHC","LU0106261612.USD","PTEN","BK4121","BK4588","BK4162","BK4196","NEO","BK4092","LU0012050646.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":10,"totalSize":200,"code":"91000000","status":"200"}]}}